title: [Therapy of hormone refractory prostate carcinoma with mitoxantrone. A clinical phase II study].
abstract: So far, no curative treatment is available for hormone-refractory prostate carcinoma. Therapy is thus focused on alleviating symptomatic tumor progression with the aim of improving quality of life. Therefore, anthracyclin-derived mitoxantrone was administered to 25 patients with hormone-refractory prostate carcinoma and symptomatic progressive disease. After a median treatment of 13 weeks, a median of 4 cycles and a follow-up of 14 months, 48% of the patients (12/25) reported improvement in tumor-related pain; in 60% (15/25) there was improvement of the self-assessment symptom score and 32% of the patients (8/25) gained weight. Additionally, partial tumor response with regression of lymph-node metastases occurred in 3/25 patients (12%). In 10/25 patients the serum level of prostate-specific antigen (PSA) decreased as well as the alkaline phosphatase (AP) in 7/25 patients. Side effects subsequent to chemotherapy were leucopenia WHO grade III in 25% of the patients and thrombocytopenia WHO grade III in 3/25 and grade V (treatment-related death) in 1/25 patients. Non-hematological toxicity occurred in 2 patients (cardiotoxicity n = 1, nephrotoxicity n = 1, WHO grade II each).
authors.affiliation: Urologische Klinik, Medizinische Einrichtungen der Universität, Gesamthochschule Essen.
authors.forename: T
authors.initials: T
authors.lastname: Otto
authors.forename: K
authors.initials: K
authors.lastname: Rembrink
authors.forename: M
authors.initials: M
authors.lastname: Goepel
authors.forename: S
authors.initials: S
authors.lastname: Krege
authors.forename: M
authors.initials: M
authors.lastname: Meyer-Schwiekerath
authors.forename: H
authors.initials: H
authors.lastname: Rübben
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use*; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D008942:Mitoxantrone
vernacular_title: Die Therapie des hormonrefraktären Prostatakarzinoms mit Mitoxantron. Eine klinische Phase-II-Studie.